BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 30308519)

  • 1. A FUS-LATS1/2 Axis Inhibits Hepatocellular Carcinoma Progression via Activating Hippo Pathway.
    Bao L; Yuan L; Li P; Bu Q; Guo A; Zhang H; Cui N; Liu B
    Cell Physiol Biochem; 2018; 50(2):437-451. PubMed ID: 30308519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promotion of LncRNA HOXA11-AS on the proliferation of hepatocellular carcinoma by regulating the expression of LATS1.
    Yu J; Hong JF; Kang J; Liao LH; Li CD
    Eur Rev Med Pharmacol Sci; 2017 Aug; 21(15):3402-3411. PubMed ID: 28829501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MEIS2C and MEIS2D promote tumor progression via Wnt/β-catenin and hippo/YAP signaling in hepatocellular carcinoma.
    Guan L; Li T; Ai N; Wang W; He B; Bai Y; Yu Z; Li M; Dong S; Zhu Q; Ding XX; Zhang S; Li M; Tang G; Xia X; Zhao J; Lin S; Yao S; Zhang L; Chen G; Liu FE; Li X; Zhang H
    J Exp Clin Cancer Res; 2019 Oct; 38(1):417. PubMed ID: 31623651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel lncRNA uc.134 represses hepatocellular carcinoma progression by inhibiting CUL4A-mediated ubiquitination of LATS1.
    Ni W; Zhang Y; Zhan Z; Ye F; Liang Y; Huang J; Chen K; Chen L; Ding Y
    J Hematol Oncol; 2017 Apr; 10(1):91. PubMed ID: 28420424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-29c-3p regulates DNMT3B and LATS1 methylation to inhibit tumor progression in hepatocellular carcinoma.
    Wu H; Zhang W; Wu Z; Liu Y; Shi Y; Gong J; Shen W; Liu C
    Cell Death Dis; 2019 Jan; 10(2):48. PubMed ID: 30718452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long noncoding RNA SchLAH suppresses metastasis of hepatocellular carcinoma through interacting with fused in sarcoma.
    Ge Z; Cheng Z; Yang X; Huo X; Wang N; Wang H; Wang C; Gu D; Zhao F; Yao M; Fan J; Qin W
    Cancer Sci; 2017 Apr; 108(4):653-662. PubMed ID: 28196303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Knockdown of yes-associated protein inhibits proliferation and downregulates large tumor suppressor 1 expression in MHCC97H human hepatocellular carcinoma cells.
    Wang C; Zhu ZM; Liu CL; He XJ; Zhang HY; Dong JH
    Mol Med Rep; 2015 Jun; 11(6):4101-8. PubMed ID: 25625370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of the long non-coding RNA SPRY4-IT1 promotes tumor cell proliferation and invasion by activating EZH2 in hepatocellular carcinoma.
    Zhou M; Zhang XY; Yu X
    Biomed Pharmacother; 2017 Jan; 85():348-354. PubMed ID: 27899259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TNFAIP8 interacts with LATS1 and promotes aggressiveness through regulation of Hippo pathway in hepatocellular carcinoma.
    Dong Q; Fu L; Zhao Y; Xie C; Li Q; Wang E
    Oncotarget; 2017 Feb; 8(9):15689-15703. PubMed ID: 28152516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LMO3 promotes hepatocellular carcinoma invasion, metastasis and anoikis inhibition by directly interacting with LATS1 and suppressing Hippo signaling.
    Cheng Y; Hou T; Ping J; Chen T; Yin B
    J Exp Clin Cancer Res; 2018 Sep; 37(1):228. PubMed ID: 30219064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LINC00659 Inhibits Hepatocellular Carcinoma Malignant Progression by Blocking Aerobic Glycolysis through FUS Recruitment and SLC10A1 Modulation.
    Chen B; Xu X; Wu W; Zheng K; Yu Y
    Anal Cell Pathol (Amst); 2023; 2023():5852963. PubMed ID: 37234237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SUMOylation of large tumor suppressor 1 at Lys751 attenuates its kinase activity and tumor-suppressor functions.
    Mei L; Yuan L; Shi W; Fan S; Tang C; Fan X; Yang W; Qian Y; Hussain M; Wu X
    Cancer Lett; 2017 Feb; 386():1-11. PubMed ID: 27847303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [High expression of DNMT3B promotes proliferation and invasion of hepatocellular carcinoma cells
    Dong G; Qiu F; Liu C; Wu H; Liu Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2019 Dec; 39(12):1443-1452. PubMed ID: 31907153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. WWC2 is an independent prognostic factor and prevents invasion via Hippo signalling in hepatocellular carcinoma.
    Zhang Y; Yan S; Chen J; Gan C; Chen D; Li Y; Wen J; Kremerskothen J; Chen S; Zhang J; Cao Y
    J Cell Mol Med; 2017 Dec; 21(12):3718-3729. PubMed ID: 28815883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-650 Promotes the Metastasis and Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma by Directly Inhibiting LATS2 Expression.
    Han LL; Yin XR; Zhang SQ
    Cell Physiol Biochem; 2018; 51(3):1179-1192. PubMed ID: 30481780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-15b in extracellular vesicles from arsenite-treated macrophages promotes the progression of hepatocellular carcinomas by blocking the LATS1-mediated Hippo pathway.
    Li J; Xue J; Ling M; Sun J; Xiao T; Dai X; Sun Q; Cheng C; Xia H; Wei Y; Chen F; Liu Q
    Cancer Lett; 2021 Jan; 497():137-153. PubMed ID: 33080309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NEDD4 promotes cell growth and motility in hepatocellular carcinoma.
    Zheng H; Ke X; Li D; Wang Q; Wang J; Liu X; Deng M; Deng X; Xue Y; Zhu Y; Wang Q
    Cell Cycle; 2018; 17(6):728-738. PubMed ID: 29480061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-1296 inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting SRPK1-mediated PI3K/AKT pathway.
    Xu Q; Liu X; Liu Z; Zhou Z; Wang Y; Tu J; Li L; Bao H; Yang L; Tu K
    Mol Cancer; 2017 Jun; 16(1):103. PubMed ID: 28606154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JCAD Promotes Progression of Nonalcoholic Steatohepatitis to Liver Cancer by Inhibiting LATS2 Kinase Activity.
    Ye J; Li TS; Xu G; Zhao YM; Zhang NP; Fan J; Wu J
    Cancer Res; 2017 Oct; 77(19):5287-5300. PubMed ID: 28775168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SPON2 Promotes M1-like Macrophage Recruitment and Inhibits Hepatocellular Carcinoma Metastasis by Distinct Integrin-Rho GTPase-Hippo Pathways.
    Zhang YL; Li Q; Yang XM; Fang F; Li J; Wang YH; Yang Q; Zhu L; Nie HZ; Zhang XL; Feng MX; Jiang SH; Tian GA; Hu LP; Lee HY; Lee SJ; Xia Q; Zhang ZG
    Cancer Res; 2018 May; 78(9):2305-2317. PubMed ID: 29440144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.